Effect of Postbiotic Product on Colonic Barriers in IBS

Status Completed

Clinical Trial Summary

Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this experimental study, we investigated whether ReFerm® has a beneficial effect on the intestinal epithelial barrier function in patients with IBS.

Clinical Trial Description

A single-blinded, randomised experimental study was conducted. Potential participants were screened based on the inclusion and exclusion criteria during telephone interviews. As the patients were their own controls, self-reported allergy was not an exclusion criterion as long as both interventions were carried out during unchanged allergic exposure. Patients were then randomly allocated to one of two study arms: Referm® or thickened water (Thick-it ®, commercially available; Kent Precision Foods Group, Inc., Muscatine, IA, USA) as placebo. The patients underwent sigmoidoscopy with biopsies obtained from the distal colon at baseline and after 14 days of intervention with ReFerm® or placebo enema twice a day. The enema was administered rectally, in the left side position, and retained for as long as possible (at least 10 min) both in the left-sided and supine body position to activate retrograde peristalsis. To assess clinical improvement of symptoms, questionnaires were completed twice: before and after the intervention. During the 14 days of the intervention, the patients completed daily questionnaires. To improve compliance with the study intervention, the patients were given a check-up call by a principal investigator (OBe) twice per week during the intervention period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05475314
Study type	Interventional
Source	Nordisk Rebalance A/S
Contact
Status	Completed
Phase	N/A
Start date	December 1, 2020
Completion date	April 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05118243` - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance	N/A
Completed	`NCT04422327` - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome	Phase 1/Phase 2
Recruiting	`NCT05178017` - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)	N/A
Completed	`NCT05197413` - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms	N/A
Completed	`NCT04905524` - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)	N/A
Recruiting	`NCT06297785` - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)	N/A
Recruiting	`NCT05874830` - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome	N/A
Active, not recruiting	`NCT04723056` - Zemedy Application for Irritable Bowel Syndrome	N/A
Completed	`NCT05565612` - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome	N/A
Recruiting	`NCT03131414` - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed	`NCT03333291` - Fecal Transplantation in Patients With IBS	N/A
Completed	`NCT03449628` - L. Casei DG® in Patients With Irritable Bowel Syndrome.	N/A
Recruiting	`NCT06215222` - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed	`NCT05016596` - Postprandial Lipids in IBS and Nutritional Treatment	N/A
Recruiting	`NCT04760353` - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome	N/A
Completed	`NCT06426745` - Split-dose Versus Single-dose Bowel Preparation for Colonoscopy	N/A
Recruiting	`NCT04217733` - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome	Phase 3
Completed	`NCT03178877` - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors	N/A
Recruiting	`NCT05990764` - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)	N/A
Completed	`NCT03948854` - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients	N/A